Sodium-glucose cotransporter 2 inhibitor effects on cardiovascular outcomes in chronic kidney disease

Shivakumar, O., Sattar, N. and Wheeler, D. C. (2020) Sodium-glucose cotransporter 2 inhibitor effects on cardiovascular outcomes in chronic kidney disease. Nephrology Dialysis Transplantation, 35(Supple), i43-i47. (doi: 10.1093/ndt/gfz292) (PMID:32003831) (PMCID:PMC6993195)

[img]
Preview
Text
211453.pdf - Published Version
Available under License Creative Commons Attribution Non-commercial.

234kB

Abstract

Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce cardiovascular events, specifically those related to heart failure in patients with type 2 diabetes. Reductions in major adverse cardiovascular event (MACE) outcomes are also observed, but confined largely to patients who have prior cardiovascular disease. Cardiovascular outcome benefits extend to patients with type 2 diabetes and reduced estimated glomerular filtration (eGFR) rate down to 30 mL/min/1.73 m2 and to patients with heart failure but without diabetes. Ongoing trials are exploring whether patients with chronic kidney disease (CKD) but without diabetes will gain similar benefits from this class of agents. Although some safety concerns have emerged, it seems likely that SGLT2 inhibitors will be used more widely in CKD patients to reduce their cardiovascular risk.

Item Type:Articles
Keywords:Cardiovascular disease, Type 2 diabetes, Heart Failure, Chronic Kidney Disease, Sglt2 Inhibitors
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Sattar, Professor Naveed
Authors: Shivakumar, O., Sattar, N., and Wheeler, D. C.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cardiovascular and Medical Sciences
Journal Name:Nephrology Dialysis Transplantation
Publisher:Oxford University Press
ISSN:0931-0509
ISSN (Online):1460-2385
Copyright Holders:Copyright © 2020 The Authors
First Published:First published in Nephrology Dialysis Transplantation 35:i43–i47
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record